Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Election of seven nominees to the Board of Directors at the 2023-01-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-01-10
Exact text from the filing
1. The seven nominees (listed below) for election to the Company’s Board of Directors (the “Board”) were elected to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes Dr. Irit Arbel 10,568,981 226,705 N/A N/A 13,073,706 Dr. June S. Almenoff 10,481,733 313,953 N/A N/A 13,073,706 Dr. Anthony Polverino 10,621,912 173,774 N/A N/A 13,073,706 Dr. Jacob Frenkel 10,637,258 158,428 N/A N/A 13,073,706 Malcolm Taub 10,516,216 279,470 N/A N/A 13,073,706 Uri Yablonka 10,597,289 198,397 N/A N/A 13,073,706 Dr. Menghisteab Bairu 10,652,336 143,350 N/A N/A 13,073,706
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the current fiscal year at the 2023-01-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-01-10
Exact text from the filing
The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year was approved, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes 23,320,844 N/A 482,449 66,099 N/A
View on SEC.gov